Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

As the pharmaceutical industry continues to push the boundaries of innovation, the role of digital solutions like eCOA platforms will only grow in significance. For rare disease trials, where patient ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

There is a topic that has, surprisingly, been the subject of controversial debate for years: do prescription products need branding? If we look at the current developments in the industry, the ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

The 4th In Vivo Cell Engineering & Gene Editing Summit, taking place June 3–5, 2025 in Boston, is the definitive event ...

The 6th Gene Therapy Analytical Development Summit Europe, taking place from 20 th – 22 nd May 2025 in London, returns as the ...